戻る Agenda
The New Business Reality for the Medical Science Liaison Community
Session Chair(s)
Kevin Charles Henderson, PHARMD, MBA
Executive Director, Hematology US Medical Affairs
Gilead Sciences, United States
The medical liaison role has experienced a dramatic transformation in the new era of industry growth and consolidation. Indeed, the explosion of small biopharmaceutical companies—coupled with their subsequent acquisition by more established, global pharmaceutical corporations—has resulted in the emergence of new business challenges facing medical liaisons requiring novel skill sets. This forum is designed to examine the medical liaison role given the internal/external business environment and to provide insight into how the role may evolve in the context of organizational growth and acquisition.
Learning Objective : Describe the business challenges facing medical liaisons from the perspective of both smaller biopharmaceutical companies and larger, global organizations; Identify common core medical liaison activities and how they may evolve and change within the context of organizational growth and acquisition; Discuss novel skill sets required to successfully address these issues across entities of various sizes and structure in the current market landscape.
Speaker(s)
Small Start-Up, Single Pipeline Molecule
Dipam Doshi, PHARMD
0140, United States
Principal Medical Science Liaison
Panelist
Paul James, PHARMD, MBA
Genentech, A Member of the Roche Group, United States
Associate Director, Medical Science Liaisons
Panelist
Kimberly Johnson, PHARMD
Eli Lilly and Company, United States
Field Medical Advisor